{"doc_id": "32579195", "type of study": "Therapy", "title": "", "abstract": "Effect of Colchicine vs Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hospitalized With Coronavirus Disease 2019: The GRECCO-19 Randomized Clinical Trial.\nImportance : Severe acute respiratory syndrome coronavirus 2 infection has evolved into a global pandemic.\nLow-dose colchicine combines anti-inflammatory action with a favorable safety profile.\nObjective : To evaluate the effect of treatment with colchicine on cardiac and inflammatory biomarkers and clinical outcomes in patients hospitalized with coronavirus disease 2019 (COVID-19).\nDesign, Setting, and Participants : In this prospective, open-label, randomized clinical trial (the Greek Study in the Effects of Colchicine in COVID-19 Complications Prevention), 105 patients hospitalized with COVID-19 were randomized in a 1:1 allocation from April 3 to April 27, 2020, to either standard medical treatment or colchicine with standard medical treatment.\nThe study took place in 16 tertiary hospitals in Greece.\nIntervention : Colchicine administration (1.5-mg loading dose followed by 0.5 mg after 60 min and maintenance doses of 0.5 mg twice daily) with standard medical treatment for as long as 3 weeks.\nMain Outcomes and Measures : Primary end points were (1) maximum high-sensitivity cardiac troponin level; (2) time for C-reactive protein to reach more than 3 times the upper reference limit; and (3) time to deterioration by 2 points on a 7-grade clinical status scale, ranging from able to resume normal activities to death.\nSecondary end points were (1) the percentage of participants requiring mechanical ventilation, (2) all-cause mortality, and (3) number, type, severity, and seriousness of adverse events.\nThe primary efficacy analysis was performed on an intention-to-treat basis.\nResults : A total of 105 patients were evaluated (61 [58.1%] men; median [interquartile range] age, 64 [54-76] years) with 50 (47.6%) randomized to the control group and 55 (52.4%) to the colchicine group.\nMedian (interquartile range) peak high-sensitivity cardiac troponin values were 0.0112 (0.0043-0.0093) ng/mL in the control group and 0.008 (0.004-0.0135) ng/mL in the colchicine group (P\u2009=\u2009.34).\nMedian (interquartile range) maximum C-reactive protein levels were 4.5 (1.4-8.9) mg/dL vs 3.1 (0.8-9.8) mg/dL (P\u2009=\u2009.73), respectively.\nThe clinical primary end point rate was 14.0% in the control group (7 of 50 patients) and 1.8% in the colchicine group (1 of 55 patients) (odds ratio, 0.11; 95% CI, 0.01-0.96; P\u2009=\u2009.02).\nMean (SD) event-free survival time was 18.6 (0.83) days the in the control group vs 20.7 (0.31) in the colchicine group (log rank P\u2009=\u2009.03).\nAdverse events were similar in the 2 groups, except for diarrhea, which was more frequent with colchicine group than the control group (25 patients [45.5%] vs 9 patients [18.0%]; P\u2009=\u2009.003).\nConclusions and Relevance : In this randomized clinical trial, participants who received colchicine had statistically significantly improved time to clinical deterioration.\nThere were no significant differences in high-sensitivity cardiac troponin or C-reactive protein levels.\nThese findings should be interpreted with caution.\nTrial Registration : ClinicalTrials.gov Identifier: NCT04326790.\n", "Evidence Map": {"Enrollment": [{"term": "Hospitalized", "negation": "affirmed", "UMLS": {}, "start": 111, "end": 123}, {"term": "Coronavirus Disease 2019", "negation": "affirmed", "UMLS": {}, "start": 129, "end": 153}, {"term": "hospitalized", "negation": "affirmed", "UMLS": {}, "start": 137, "end": 149}, {"term": "coronavirus disease 2019 (", "negation": "affirmed", "UMLS": {}, "start": 155, "end": 181}, {"term": "hospitalized", "negation": "affirmed", "UMLS": {}, "start": 200, "end": 212}, {"term": "COVID-19", "negation": "affirmed", "UMLS": {}, "start": 149, "end": 157}], "Comparison Results": [], "Study Arm 1 Results": [], "Study Arm 2 Results": [], "Hypothesis": []}, "Sentence-level breakdown": [{"Section": "TITLE", "Text": "Effect of Colchicine vs Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hospitalized With Coronavirus Disease 2019 : The GRECCO-19 Randomized Clinical Trial .", "Evidence Elements": {"Participant": [{"term": "Hospitalized", "negation": "affirmed", "UMLS": {}, "start": 111, "end": 123}, {"term": "Coronavirus Disease 2019", "negation": "affirmed", "UMLS": {}, "start": 129, "end": 153}], "Intervention": [{"term": "Colchicine", "negation": "affirmed", "UMLS": {}, "start": 10, "end": 20, "has_chemical": [{"text": "colchicine", "maps_to": "C0009262:colchicine", "start": 0, "end": 10}], "has_relation": "N/A"}, {"term": "Standard Care", "negation": "affirmed", "UMLS": {}, "start": 24, "end": 37, "has_relation": "N/A"}], "Outcome": [{"term": "Cardiac and Inflammatory Biomarkers", "negation": "affirmed", "UMLS": {}, "start": 41, "end": 76}, {"term": "Clinical Outcomes", "negation": "affirmed", "UMLS": {}, "start": 81, "end": 98}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Importance : Severe acute respiratory syndrome coronavirus 2 infection has evolved into a global pandemic .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Low-dose colchicine combines anti-inflammatory action with a favorable safety profile .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "Low-dose colchicine", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 19, "has_chemical": [{"text": "colchicine", "maps_to": "C0009262:colchicine", "start": 9, "end": 19, "has_dosage": ["low dose"]}], "has_relation": "N/A"}], "Outcome": [{"term": "anti-inflammatory action", "negation": "affirmed", "UMLS": {}, "start": 29, "end": 53}, {"term": "safety", "negation": "affirmed", "UMLS": {}, "start": 71, "end": 77}], "Observation": [{"term": "favorable", "negation": "affirmed", "UMLS": {}, "start": 61, "end": 70}], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Objective : To evaluate the effect of treatment with colchicine on cardiac and inflammatory biomarkers and clinical outcomes in patients hospitalized with coronavirus disease 2019 ( COVID-19 ) .", "Evidence Elements": {"Participant": [{"term": "hospitalized", "negation": "affirmed", "UMLS": {}, "start": 137, "end": 149}, {"term": "coronavirus disease 2019 (", "negation": "affirmed", "UMLS": {}, "start": 155, "end": 181}], "Intervention": [{"term": "colchicine", "negation": "affirmed", "UMLS": {}, "start": 53, "end": 63, "has_chemical": [{"text": "colchicine", "maps_to": "C0009262:colchicine", "start": 0, "end": 10}], "has_relation": "N/A"}], "Outcome": [{"term": "cardiac and inflammatory biomarkers", "negation": "affirmed", "UMLS": {}, "start": 67, "end": 102}, {"term": "clinical outcomes", "negation": "affirmed", "UMLS": {}, "start": 107, "end": 124}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Design , Setting , and Participants : In this prospective , open-label , randomized clinical trial ( the Greek Study in the Effects of Colchicine in COVID-19 Complications Prevention ) , 105 patients hospitalized with COVID-19 were randomized in a 1:1 allocation from April 3 to April 27 , 2020 , to either standard medical treatment or colchicine with standard medical treatment .", "Evidence Elements": {"Participant": [{"term": "hospitalized", "negation": "affirmed", "UMLS": {}, "start": 200, "end": 212}, {"term": "COVID-19", "negation": "affirmed", "UMLS": {}, "start": 149, "end": 157}], "Intervention": [{"term": "Colchicine", "negation": "affirmed", "UMLS": {}, "start": 135, "end": 145, "has_chemical": [{"text": "colchicine", "maps_to": "C0009262:colchicine", "start": 0, "end": 10}], "has_relation": "N/A"}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "The study took place in 16 tertiary hospitals in Greece .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Intervention : Colchicine administration ( 1.5-mg loading dose followed by 0.5 mg after 60 min and maintenance doses of 0.5 mg twice daily ) with standard medical treatment for as long as 3 weeks .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "Colchicine", "negation": "affirmed", "UMLS": {}, "start": 15, "end": 25, "has_chemical": [{"text": "colchicine", "maps_to": "C0009262:colchicine", "start": 0, "end": 10}], "has_relation": "N/A"}, {"term": "standard medical treatment", "negation": "affirmed", "UMLS": {}, "start": 146, "end": 172, "has_procedure": [{"text": "standard medical treatment", "maps_to": "C0087111:treatment", "start": 0, "end": 26}], "has_relation": "N/A"}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Main Outcomes and Measures : Primary end points were ( 1 ) maximum high-sensitivity cardiac troponin level ; ( 2 ) time for C-reactive protein to reach more than 3 times the upper reference limit ; and ( 3 ) time to deterioration by 2 points on a 7-grade clinical status scale , ranging from able to resume normal activities to death .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [{"term": "maximum high-sensitivity cardiac troponin level", "negation": "affirmed", "UMLS": {}, "start": 59, "end": 106}, {"term": "time for C-reactive protein to reach more than 3 times the upper reference limit", "negation": "affirmed", "UMLS": {}, "start": 115, "end": 195}, {"term": "time to deterioration by 2 points", "negation": "affirmed", "UMLS": {}, "start": 208, "end": 241}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Secondary end points were ( 1 ) the percentage of participants requiring mechanical ventilation , ( 2 ) all-cause mortality , and ( 3 ) number , type , severity , and seriousness of adverse events .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [{"term": "percentage of participants requiring mechanical ventilation", "negation": "affirmed", "UMLS": {}, "start": 36, "end": 95}, {"term": "all-cause mortality", "negation": "affirmed", "UMLS": {}, "start": 104, "end": 123}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "The primary efficacy analysis was performed on an intention-to-treat basis .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Results : A total of 105 patients were evaluated ( 61 [ 58.1 % ] men ; median [ interquartile range ] age , 64 [ 54-76 ] years ) with 50 ( 47.6 % ) randomized to the control group and 55 ( 52.4 % ) to the colchicine group .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Median ( interquartile range ) peak high-sensitivity cardiac troponin values were 0.0112 ( 0.0043-0.0093 ) ng / mL in the control group and 0.008 ( 0.004-0.0135 ) ng / mL in the colchicine group ( P =.34 ) .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "control", "negation": "affirmed", "UMLS": {}, "start": 122, "end": 129, "has_relation": "N/A"}], "Outcome": [{"term": "Median ( interquartile range ) peak high-sensitivity cardiac troponin values", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 76}], "Observation": [{"term": "0.0112 ( 0.0043-0.0093 )", "negation": "affirmed", "UMLS": {}, "start": 82, "end": 106}, {"term": "mL", "negation": "affirmed", "UMLS": {}, "start": 112, "end": 114}, {"term": "0.008 ( 0.004-0.0135 )", "negation": "affirmed", "UMLS": {}, "start": 140, "end": 162}, {"term": "mL", "negation": "affirmed", "UMLS": {}, "start": 112, "end": 114}], "Count": []}, "Evidence Propositions": [{"Intervention": {"term": "control", "has_relation": "N/A"}, "Observation": "0.0112 ( 0.0043-0.0093 )", "Outcome": "Median ( interquartile range ) peak high-sensitivity cardiac troponin values", "Count": ""}, {"Intervention": {"term": "control", "has_relation": "N/A"}, "Observation": "mL", "Outcome": "Median ( interquartile range ) peak high-sensitivity cardiac troponin values", "Count": ""}]}, {"Section": "UNKNOWN", "Text": "Median ( interquartile range ) maximum C-reactive protein levels were 4.5 ( 1.4-8.9 ) mg / dL vs 3.1 ( 0.8-9.8 ) mg / dL ( P =.73 ) , respectively .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [{"term": "Median ( interquartile range ) maximum C-reactive protein levels", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 64}], "Observation": [{"term": "4.5 ( 1.4-8.9 )", "negation": "affirmed", "UMLS": {}, "start": 70, "end": 85}, {"term": "dL", "negation": "affirmed", "UMLS": {}, "start": 91, "end": 93}, {"term": "3.1 ( 0.8-9.8 )", "negation": "affirmed", "UMLS": {}, "start": 97, "end": 112}], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "The clinical primary end point rate was 14.0 % in the control group ( 7 of 50 patients ) and 1.8 % in the colchicine group ( 1 of 55 patients ) ( odds ratio , 0.11 ; 95 % CI , 0.01-0.96 ; P =.02 ) .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "control", "negation": "affirmed", "UMLS": {}, "start": 54, "end": 61, "has_relation": "N/A"}, {"term": "colchicine", "negation": "affirmed", "UMLS": {}, "start": 106, "end": 116, "has_chemical": [{"text": "colchicine", "maps_to": "C0009262:colchicine", "start": 0, "end": 10}], "has_relation": "N/A"}], "Outcome": [{"term": "clinical primary end point rate", "negation": "affirmed", "UMLS": {}, "start": 4, "end": 35}], "Observation": [{"term": "14.0 %", "negation": "affirmed", "UMLS": {}, "start": 40, "end": 46}, {"term": "1.8 %", "negation": "affirmed", "UMLS": {}, "start": 93, "end": 98}], "Count": [{"term": "7 of 50 patients", "negation": "affirmed", "UMLS": {}, "start": 70, "end": 86}, {"term": "1 of 55 patients", "negation": "affirmed", "UMLS": {}, "start": 125, "end": 141}]}, "Evidence Propositions": [{"Intervention": {"term": "control", "has_relation": "N/A"}, "Observation": "14.0 %", "Outcome": "clinical primary end point rate", "Count": ""}, {"Intervention": {"term": "colchicine", "has_chemical": [{"text": "colchicine", "maps_to": "C0009262:colchicine", "start": 0, "end": 10}], "has_relation": "N/A"}, "Observation": "1.8 %", "Outcome": "clinical primary end point rate", "Count": ""}, {"Intervention": {"term": "control", "has_relation": "N/A"}, "Observation": "", "Count": "7 of 50 patients", "Outcome": "clinical primary end point rate"}]}, {"Section": "UNKNOWN", "Text": "Mean ( SD ) event-free survival time was 18.6 ( 0.83 ) days the in the control group vs 20.7 ( 0.31 ) in the colchicine group ( log rank P = .03 ) .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "control", "negation": "affirmed", "UMLS": {}, "start": 71, "end": 78, "has_relation": "N/A"}, {"term": "colchicine", "negation": "affirmed", "UMLS": {}, "start": 109, "end": 119, "has_chemical": [{"text": "colchicine", "maps_to": "C0009262:colchicine", "start": 0, "end": 10}], "has_relation": "N/A"}], "Outcome": [{"term": "Mean ( SD ) event-free survival time", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 36}], "Observation": [{"term": "18.6 ( 0.83 ) days", "negation": "affirmed", "UMLS": {}, "start": 41, "end": 59}, {"term": "20.7 ( 0.31 )", "negation": "affirmed", "UMLS": {}, "start": 88, "end": 101}], "Count": []}, "Evidence Propositions": [{"Intervention": {"term": "control", "has_relation": "N/A"}, "Observation": "18.6 ( 0.83 ) days", "Outcome": "Mean ( SD ) event-free survival time", "Count": ""}, {"Intervention": {"term": "colchicine", "has_chemical": [{"text": "colchicine", "maps_to": "C0009262:colchicine", "start": 0, "end": 10}], "has_relation": "N/A"}, "Observation": "20.7 ( 0.31 )", "Outcome": "Mean ( SD ) event-free survival time", "Count": ""}]}, {"Section": "UNKNOWN", "Text": "Adverse events were similar in the 2 groups , except for diarrhea , which was more frequent with colchicine group than the control group ( 25 patients [ 45.5 % ] vs 9 patients [ 18.0 % ] ; P = .003 ) .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "2 groups", "negation": "affirmed", "UMLS": {}, "start": 35, "end": 43, "has_relation": "N/A"}, {"term": "colchicine", "negation": "negated", "UMLS": {}, "start": 97, "end": 107, "has_chemical": [{"text": "colchicine", "maps_to": "C0009262:colchicine", "start": 0, "end": 10}], "has_relation": "N/A"}, {"term": "control", "negation": "negated", "UMLS": {}, "start": 123, "end": 130, "has_relation": "N/A"}], "Outcome": [{"term": "Adverse events", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 14}, {"term": "diarrhea", "negation": "negated", "UMLS": {}, "start": 57, "end": 65}], "Observation": [{"term": "similar", "negation": "affirmed", "UMLS": {}, "start": 20, "end": 27}, {"term": "more frequent", "negation": "negated", "UMLS": {}, "start": 78, "end": 91}], "Count": [{"term": "25 patients [ 45.5 % ]", "negation": "affirmed", "UMLS": {}, "start": 139, "end": 161}]}, "Evidence Propositions": [{"Intervention": [{"term": "2 groups", "has_relation": "N/A"}], "Observation": "similar", "Outcome": "Adverse events", "Count": ""}, {"Intervention": [{"term": "colchicine", "has_chemical": [{"text": "colchicine", "maps_to": "C0009262:colchicine", "start": 0, "end": 10}], "has_relation": "N/A"}, {"term": "control", "has_relation": "N/A"}], "Observation": "more frequent", "Outcome": "Adverse events", "Count": ""}, {"Intervention": [{"term": "colchicine", "has_chemical": [{"text": "colchicine", "maps_to": "C0009262:colchicine", "start": 0, "end": 10}], "has_relation": "N/A"}, {"term": "control", "has_relation": "N/A"}], "Observation": "more frequent", "Outcome": "diarrhea", "Count": ""}, {"Intervention": {"term": "2 groups", "has_relation": "N/A"}, "Observation": "", "Count": "25 patients [ 45.5 % ]", "Outcome": "Adverse events"}, {"Intervention": {"term": "colchicine", "has_chemical": [{"text": "colchicine", "maps_to": "C0009262:colchicine", "start": 0, "end": 10}], "has_relation": "N/A"}, "Observation": "", "Count": "25 patients [ 45.5 % ]", "Outcome": "Adverse events"}]}, {"Section": "UNKNOWN", "Text": "Conclusions and Relevance : In this randomized clinical trial , participants who received colchicine had statistically significantly improved time to clinical deterioration .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "colchicine", "negation": "affirmed", "UMLS": {}, "start": 90, "end": 100, "has_chemical": [{"text": "colchicine", "maps_to": "C0009262:colchicine", "start": 0, "end": 10}], "has_relation": "N/A"}], "Outcome": [{"term": "time to clinical", "negation": "affirmed", "UMLS": {}, "start": 142, "end": 158}], "Observation": [{"term": "statistically significantly improved", "negation": "affirmed", "UMLS": {}, "start": 105, "end": 141}], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "There were no significant differences in high-sensitivity cardiac troponin or C-reactive protein levels .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [{"term": "high-sensitivity cardiac troponin", "negation": "negated", "UMLS": {}, "start": 41, "end": 74}, {"term": "C-reactive protein levels", "negation": "negated", "UMLS": {}, "start": 78, "end": 103}], "Observation": [{"term": "significant differences", "negation": "affirmed", "UMLS": {}, "start": 14, "end": 37}], "Count": []}, "Evidence Propositions": [{"Intervention": [], "Observation": "significant differences", "Outcome": "high-sensitivity cardiac troponin", "Count": ""}, {"Intervention": [], "Observation": "significant differences", "Outcome": "C-reactive protein levels", "Count": ""}]}, {"Section": "UNKNOWN", "Text": "These findings should be interpreted with caution .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Trial Registration : ClinicalTrials.gov Identifier : NCT04326790 .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}]}